ES2659092B2 - Composición farmaceútica que comprende inhibidores selectivos de la recaptación de la serotonina y galanina (1-15) - Google Patents

Composición farmaceútica que comprende inhibidores selectivos de la recaptación de la serotonina y galanina (1-15) Download PDF

Info

Publication number: ES2659092B2
Authority: ES; Spain
Prior art keywords: pharmaceutical composition; gal; flx; composition according; administration
Prior art date: 2017-02-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES201730214A

Other languages

English (en)

Spanish (es)

Other versions

ES2659092A1 (es

Inventor

Antonio FLORES BURGESS

Carmelo MILLÓN PEÑUELA

Belén GAGO CALDERÓN

Manuel Alejandro NARVÁEZ PELÁEZ

José Ángel NARVÁEZ BUENO

Luis Javier SANTÍN NÚÑEZ

Zaida DÍAZ CABIALE

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Universidad de Malaga

Original Assignee

Universidad de Malaga

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-20

Filing date

2017-02-20

Publication date

2018-06-29

2017-02-20 Application filed by Universidad de Malaga filed Critical Universidad de Malaga

2017-02-20 Priority to ES201730214A priority Critical patent/ES2659092B2/es

2018-02-20 Priority to PCT/ES2018/070121 priority patent/WO2018150073A1/fr

2018-03-13 Publication of ES2659092A1 publication Critical patent/ES2659092A1/es

2018-06-29 Application granted granted Critical

2018-06-29 Publication of ES2659092B2 publication Critical patent/ES2659092B2/es

Status Active legal-status Critical Current

2037-02-20 Anticipated expiration legal-status Critical

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 title abstract description 213
101800002068 Galanin Proteins 0.000 title abstract description 124
102000019432 Galanin Human genes 0.000 title abstract description 124
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract description 64
229940076279 serotonin Drugs 0.000 title abstract description 22
239000003112 inhibitor Substances 0.000 title abstract description 5
150000001875 compounds Chemical class 0.000 claims abstract description 29
150000003839 salts Chemical class 0.000 claims abstract description 26
LOXLDVDBPRBBLT-GDRYISODSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-h Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 LOXLDVDBPRBBLT-GDRYISODSA-N 0.000 claims abstract 3
108010063090 galanin (1-15) Proteins 0.000 claims abstract 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 115
229960002464 fluoxetine Drugs 0.000 claims description 113
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 27
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 27
238000011282 treatment Methods 0.000 claims description 27
239000004480 active ingredient Substances 0.000 claims description 22
208000019901 Anxiety disease Diseases 0.000 claims description 19
239000002552 dosage form Substances 0.000 claims description 14
208000020401 Depressive disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 6
208000032841 Bulimia Diseases 0.000 claims description 6
206010006550 Bulimia nervosa Diseases 0.000 claims description 6
208000030814 Eating disease Diseases 0.000 claims description 6
208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
208000008589 Obesity Diseases 0.000 claims description 6
206010036618 Premenstrual syndrome Diseases 0.000 claims description 6
208000022531 anorexia Diseases 0.000 claims description 6
229960001653 citalopram Drugs 0.000 claims description 6
208000010877 cognitive disease Diseases 0.000 claims description 6
206010061428 decreased appetite Diseases 0.000 claims description 6
235000014632 disordered eating Nutrition 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
208000024732 dysthymic disease Diseases 0.000 claims description 6
235000020824 obesity Nutrition 0.000 claims description 6
208000019899 phobic disease Diseases 0.000 claims description 6
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 5
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 5
206010013654 Drug abuse Diseases 0.000 claims description 5
208000030990 Impulse-control disease Diseases 0.000 claims description 5
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 5
230000036506 anxiety Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 5
229960004341 escitalopram Drugs 0.000 claims description 5
229960004038 fluvoxamine Drugs 0.000 claims description 5
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 5
229960002296 paroxetine Drugs 0.000 claims description 5
229960002073 sertraline Drugs 0.000 claims description 5
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 5
208000011117 substance-related disease Diseases 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 4
239000012634 fragment Substances 0.000 claims description 4
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 3
208000026345 acute stress disease Diseases 0.000 claims description 3
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
230000006735 deficit Effects 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims description 2
208000013403 hyperactivity Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 3
239000003772 serotonin uptake inhibitor Substances 0.000 abstract description 50
229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract description 41
230000001225 therapeutic effect Effects 0.000 abstract description 15
102000017911 HTR1A Human genes 0.000 abstract description 3
101150015707 HTR1A gene Proteins 0.000 abstract description 3
230000015572 biosynthetic process Effects 0.000 abstract description 3
230000001242 postsynaptic effect Effects 0.000 abstract description 3
238000003786 synthesis reaction Methods 0.000 abstract description 3
230000000694 effects Effects 0.000 description 49
238000002347 injection Methods 0.000 description 45
239000007924 injection Substances 0.000 description 45
238000012360 testing method Methods 0.000 description 41
238000012048 forced swim test Methods 0.000 description 38
241000700159 Rattus Species 0.000 description 33
102000001968 Galanin receptor 2 Human genes 0.000 description 31
108050009373 Galanin receptor 2 Proteins 0.000 description 31
230000037120 immobility Effects 0.000 description 31
230000009182 swimming Effects 0.000 description 29
238000011260 co-administration Methods 0.000 description 28
230000001430 anti-depressive effect Effects 0.000 description 23
230000009194 climbing Effects 0.000 description 15
239000005557 antagonist Substances 0.000 description 14
239000000935 antidepressant agent Substances 0.000 description 14
238000002474 experimental method Methods 0.000 description 14
229940005513 antidepressants Drugs 0.000 description 13
210000001175 cerebrospinal fluid Anatomy 0.000 description 13
230000003993 interaction Effects 0.000 description 12
LWRJZIPAGMGXQJ-DIJVWCDGSA-N org-6582 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@@H]2[C@@H](N)[C@H]1C=CC2 LWRJZIPAGMGXQJ-DIJVWCDGSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 10
230000006399 behavior Effects 0.000 description 10
238000001543 one-way ANOVA Methods 0.000 description 10
230000009471 action Effects 0.000 description 9
230000003542 behavioural effect Effects 0.000 description 9
210000005110 dorsal hippocampus Anatomy 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
210000001320 hippocampus Anatomy 0.000 description 8
XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 description 7
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 7
238000011201 multiple comparisons test Methods 0.000 description 7
108020004459 Small interfering RNA Proteins 0.000 description 6
238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 6
230000027455 binding Effects 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000003826 tablet Substances 0.000 description 6
208000019022 Mood disease Diseases 0.000 description 5
-1 R-FLX Chemical compound 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000000556 agonist Substances 0.000 description 5
238000000211 autoradiogram Methods 0.000 description 5
239000002775 capsule Substances 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
230000004044 response Effects 0.000 description 5
238000009227 behaviour therapy Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
XIGAHNVCEFUYOV-UHFFFAOYSA-N but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)C=CC(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-UHFFFAOYSA-N 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
238000007901 in situ hybridization Methods 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000003307 slaughter Methods 0.000 description 4
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 3
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 3
206010041250 Social phobia Diseases 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000001690 micro-dialysis Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000003727 serotonin 1A antagonist Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102000007527 Autoreceptors Human genes 0.000 description 2
108010071131 Autoreceptors Proteins 0.000 description 2
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
108700018427 F 327 Proteins 0.000 description 2
201000001880 Sexual dysfunction Diseases 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229960004606 clomipramine Drugs 0.000 description 2
USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 2
229960005217 dapoxetine Drugs 0.000 description 2
210000001947 dentate gyrus Anatomy 0.000 description 2
238000000586 desensitisation Methods 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 2
229950003930 femoxetine Drugs 0.000 description 2
229960004801 imipramine Drugs 0.000 description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229960001800 nefazodone Drugs 0.000 description 2
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000001050 pharmacotherapy Methods 0.000 description 2
239000006187 pill Substances 0.000 description 2
208000028173 post-traumatic stress disease Diseases 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000004000 serotonin 1B antagonist Substances 0.000 description 2
230000000697 serotonin reuptake Effects 0.000 description 2
231100000872 sexual dysfunction Toxicity 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
229960004688 venlafaxine Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
WIQRCHMSJFFONW-HNNXBMFYSA-N (3s)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound O([C@@H](CCN)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-HNNXBMFYSA-N 0.000 description 1
XFPJZGUGGRESHD-PHJLCXHGSA-N (6r,10br)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline;hydrobromide Chemical compound Br.ClC1=CC=CC=C1[C@H]1C2=CC=CC=C2[C@H]2CCCN2C1 XFPJZGUGGRESHD-PHJLCXHGSA-N 0.000 description 1
PBALTVQMQFVDBV-GRTNUQQKSA-N (6s,10br)-6-(4-methylsulfanylphenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline;perchloric acid Chemical compound OCl(=O)(=O)=O.C1=CC(SC)=CC=C1[C@H]1C2=CC=CC=C2[C@H]2CCCN2C1 PBALTVQMQFVDBV-GRTNUQQKSA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
WETRBJOSGIDJHQ-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-ylmethyl)-4,5-dihydro-1h-imidazole Chemical compound C=1C2=CC=CC=C2CCC=1CC1=NCCN1 WETRBJOSGIDJHQ-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
FWYRGHMKHZXXQX-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(CO)CC1=CC=C(Cl)C(Cl)=C1 FWYRGHMKHZXXQX-UHFFFAOYSA-N 0.000 description 1
102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 1
RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
108020004518 RNA Probes Proteins 0.000 description 1
239000003391 RNA probe Substances 0.000 description 1
101100447611 Rattus norvegicus Galr1 gene Proteins 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 description 1
229960003225 alaproclate Drugs 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
229960002980 amitriptyline oxide Drugs 0.000 description 1
ZPMKQFOGINQDAM-UHFFFAOYSA-N amitriptylinoxide Chemical compound C1CC2=CC=CC=C2C(=CCC[N+](C)([O-])C)C2=CC=CC=C21 ZPMKQFOGINQDAM-UHFFFAOYSA-N 0.000 description 1
229960002519 amoxapine Drugs 0.000 description 1
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
229950005683 bazinaprine Drugs 0.000 description 1
KRNDIPHOJLIHRI-UHFFFAOYSA-N bazinaprine Chemical compound N#CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 KRNDIPHOJLIHRI-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229950000303 cericlamine Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 description 1
229950002663 clovoxamine Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
229950007329 diclofensine Drugs 0.000 description 1
ZJDCGVDEEHWEIG-UHFFFAOYSA-N diclofensine Chemical compound C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 ZJDCGVDEEHWEIG-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
229960003441 imipramine oxide Drugs 0.000 description 1
QZIQORUGXBPDSU-UHFFFAOYSA-N imipramine oxide Chemical compound C1CC2=CC=CC=C2N(CCC[N+](C)([O-])C)C2=CC=CC=C21 QZIQORUGXBPDSU-UHFFFAOYSA-N 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
SVFXPTLYMIXFRX-BBRMVZONSA-N indatraline Chemical compound C1([C@@H]2C[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 SVFXPTLYMIXFRX-BBRMVZONSA-N 0.000 description 1
229950008889 indatraline Drugs 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000008517 inhibition of serotonin uptake Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
229910052808 lithium carbonate Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960000600 milnacipran Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000004050 mood stabilizer Substances 0.000 description 1
229940127237 mood stabilizer Drugs 0.000 description 1
230000008450 motivation Effects 0.000 description 1
QXLNAYIFEMXTDZ-UHFFFAOYSA-N n-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-[2-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]benzamide Chemical compound C1=C(N2CCN(C)CC2)C(OC)=CC=C1NC(=O)C(C=C1)=CC=C1C(C(=C1)C)=CC=C1C1=NN=C(C)O1 QXLNAYIFEMXTDZ-UHFFFAOYSA-N 0.000 description 1
YYWKMPCKXDNMTJ-UHFFFAOYSA-N n-[[1-[(6-fluoronaphthalen-2-yl)methyl]piperidin-4-yl]carbamoyl]pyridine-3-carboxamide Chemical compound C1=CC2=CC(F)=CC=C2C=C1CN(CC1)CCC1NC(=O)NC(=O)C1=CC=CN=C1 YYWKMPCKXDNMTJ-UHFFFAOYSA-N 0.000 description 1
229950000323 napamezole Drugs 0.000 description 1
229960000751 nefopam Drugs 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
229950001527 nitroxazepine Drugs 0.000 description 1
CGYWLLGTCBIGSR-UHFFFAOYSA-N nitroxazepine Chemical compound O=C1N(CCCN(C)C)C2=CC=CC=C2OC2=CC=C([N+]([O-])=O)C=C21 CGYWLLGTCBIGSR-UHFFFAOYSA-N 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
238000000424 optical density measurement Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000011422 pharmacological therapy Methods 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
229950002220 pirlindole Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229960000279 quinupramine Drugs 0.000 description 1
JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
229950000319 seproxetine Drugs 0.000 description 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
229960004425 sibutramine Drugs 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000002672 stereotactic surgery Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
229960003991 trazodone Drugs 0.000 description 1
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229940035722 triiodothyronine Drugs 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
229950006360 viqualine Drugs 0.000 description 1
XFXANHWIBFMEOY-JKSUJKDBSA-N viqualine Chemical compound C12=CC(OC)=CC=C2N=CC=C1CCC[C@@H]1CCNC[C@@H]1C=C XFXANHWIBFMEOY-JKSUJKDBSA-N 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES201730214A 2017-02-20 2017-02-20 Composición farmaceútica que comprende inhibidores selectivos de la recaptación de la serotonina y galanina (1-15) Active ES2659092B2 (es)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
ES201730214A ES2659092B2 (es)	2017-02-20	2017-02-20	Composición farmaceútica que comprende inhibidores selectivos de la recaptación de la serotonina y galanina (1-15)
PCT/ES2018/070121 WO2018150073A1 (fr)	2017-02-20	2018-02-20	Composition pharmaceutique comprenant des inhibiteurs sélectifs de la recapture de la sérotonine et de la galanine (1-15)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES201730214A ES2659092B2 (es)	2017-02-20	2017-02-20	Composición farmaceútica que comprende inhibidores selectivos de la recaptación de la serotonina y galanina (1-15)

Publications (2)

Publication Number	Publication Date
ES2659092A1 ES2659092A1 (es)	2018-03-13
ES2659092B2 true ES2659092B2 (es)	2018-06-29

Family

ID=61558409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES201730214A Active ES2659092B2 (es)	2017-02-20	2017-02-20	Composición farmaceútica que comprende inhibidores selectivos de la recaptación de la serotonina y galanina (1-15)

Country Status (2)

Country	Link
ES (1)	ES2659092B2 (fr)
WO (1)	WO2018150073A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20220265601A1 (en) *	2021-02-10	2022-08-25	David Alan Heldreth, JR.	Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.

2017
- 2017-02-20 ES ES201730214A patent/ES2659092B2/es active Active
2018
- 2018-02-20 WO PCT/ES2018/070121 patent/WO2018150073A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2018150073A1 (fr)	2018-08-23
ES2659092A1 (es)	2018-03-13

Publication	Publication Date	Title
Marek	2018	Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons
US20100267772A1 (en)	2010-10-21	Combination of a Serotonin Reuptake Inhibitor and Agomelatine
Pandey et al.	2010	A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: Approaching early-onset antidepressants
Dawson et al.	2002	Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex
US20120258984A1 (en)	2012-10-11	5-htp combination therapy
Zaini et al.	2018	The use of antidepressants for physical and psychological symptoms in cancer
Li et al.	2014	Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats
ES2659092B2 (es)	2018-06-29	Composición farmaceútica que comprende inhibidores selectivos de la recaptación de la serotonina y galanina (1-15)
ES2282632T3 (es)	2007-10-16	Terapia de combinacion en la que se usa un inhibidor de la reabsorcion de serotonina.
Perez-Palomar et al.	2018	Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram
Warneck et al.	2008	Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret
US20070117844A1 (en)	2007-05-24	5-HTP combination therapy
JP2007504181A (ja)	2007-03-01	セロトニン再取り込み阻害剤およびロキサピンの併用
US20070042014A1 (en)	2007-02-22	Combination of a serotonin reuptake inhibitor and loxapine
KR20060066729A (ko)	2006-06-16	우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합
Seguí et al.	2010	Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study
JP2007504180A (ja)	2007-03-01	セロトニン再取り込み阻害剤およびアモキサピンの併用
Chen	2022	Developing Novel Prophylactic Interventions for the Prevention of Stress-Induced Psychiatric Disease
ZA200601463B (en)	2007-05-30	The combination of a serotonin reuptake inhibitor and amoxapine
CA2655846A1 (fr)	2008-11-20	Polytherapie a base de 5-htp
ES2361507T3 (es)	2011-06-17	La combinación de un inhibidor de reabsorción de la serotonina y agomelatina.
Panditrao et al.	2016	Effect of Paracetamol on the activity of drugs modulating the serotonergic system
Li	2018	CNS drug-drug interactions mediated by p-glycoprotein
Karni et al.	2006	P. 2. d. 010 Characterization of post synaptic effects of antidepressant drugs in glial cell model
Gonul	2007	Çagdas Eker1 and Ozlem Donat Eker1

Legal Events

Date	Code	Title	Description
2018-06-29	FG2A	Definitive protection	Ref document number: 2659092 Country of ref document: ES Kind code of ref document: B2 Effective date: 20180629

Date

Code

Title

Description

2018-06-29

FG2A

Definitive protection

Ref document number: 2659092

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20180629